This year, cancer research is moving at an exciting pace towards a real transformation. Just last month, the U.S. Food and Drug Administration approved a cancer treatment based on a biomarker rather than the body location where the cancer originates. ...
After six months of hard work and dedication, we are delighted to officially announce the launch of the new and improved www.nfcr.org....
Just last week, the U.S. Food and Drug Administration approved the cancer medicine— Keytruda® (generic name pembrolizumab)— to treat cancers that have a specific genetic mutation or biomarker. This is the first time a cancer treatment has been approved based on a biomarker rather than...
Targeting HER3 could cripple metastatic cancers that have spread to the brain. (Bethesda, MD, June 5, 2017) Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has...
Founded in 1964, the American Society of Clinical Oncology (ASCO®) is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. Each year, tens of thousands of oncology professionals, cancer researchers and patient advocates gather at The ASCO Annual Meeting ...
NFCR President receives the inaugural award from Society for Neuro-Oncology of the Chinese Medical Doctor Association for her outstanding contribution to international cooperation in March 2017. [caption id="attachment_13570" align="aligncenter" width="486"] From left to right: Wenbin, Li, Tao Jiang, Sujuan Ba, Webster Cavenee[/caption] Dr. Jiang Tao, the Chairman...
[vc_row][vc_column][vc_column_text] InhibOx Receives Investment to Fight Drug-Resistant Bacteria The National Foundation for Cancer Research is delighted that computer-aided drug-resistance research is now getting increased funding across the pond! NFCR lauds the selection of InhibOx Ltd. as the company to receive a nearly £1 million grant from Innovate...
Dr. Web Cavenee and Dr. Paul B. Fisher discover a new pharmacological agent to treat glioblastoma multiforme (GBM), the deadliest brain cancer....
NBTS held its annual Gray Gala and pioneers in brain tumor research were honored, including Dr. Web Cavanee, Chairman of NFCR’s Scientific Advisory Board....
Dr. Daniel Von Hoff, Director of the NFCR Center for Targeted Cancer Therapies at TGen, has been selected as a 2016 Giants of Cancer Care® by OncLive....
Search NFCR
Popular searches